MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes

In Europe, the ACS in vitro diagnostics market is dominated by a single biomarker test, cardiac troponins. However, this market remains of high interest due to advancements in assay sensitivity both on laboratory and point-of-care platforms. GlobalData expects these advancements to have an impact on other diagnostic tests such as creatine kinase-MB isoenzyme and myoglobin. Furthermore, the emergence of pipeline biomarker tests will change the landscape of ACS in vitro diagnostic testing and is expected to provide enhancements in the early diagnosis of the disease.

Full Report Details at
- http://www.fastmr.com/prod/598822_medipoint_diagnostic_cardiac_biomarkers_for_acute.aspx?afid=303

Acute coronary syndrome (ACS) consists of two major diseases, myocardial infarction (MI) and unstable angina, with the former being one of the major killers in the mature markets. Though the incidence of ACS is either in decline or steady across the US and European countries, millions of ACS and suspected ACS patients still visit emergency rooms every year with symptoms such as chest pain, and these patients are typically assessed with in vitro diagnostic cardiac biomarker tests. The ACS diagnostic cardiac biomarker reagents market is dominated by the cardiac troponins, the gold-standard biomarkers for the diagnosis of MI.

Scope

* An overview of ACS, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
* Annualized EU ACS in vitro diagnostic testing reagents market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018.
* Investigation of current and future market competition for diagnostic cardiac biomarkers for ACS
* Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
* Competitor assessment including device approval analysis and device sales forecasts.
* Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
* Analysis of unmet needs within the market and opportunities for future players.
* Technology trends evaluation to assess strength of pipeline.
* An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
* Company profiles including business description, financial overview and SWOT analysis.
* Coverage of key market players.
* Strategic assessment of the diagnostic cardiac biomarkers for ACS sector through market impact analysis, future market scenario and company analysis.
* Direct quotes from Key Opinion Leaders (KOL) as well as cardiologists

Reasons to Get this Report

* Understand the trends shaping and driving EU diagnostic cardiac biomarkers for ACS.
* Realize device preferences of physicians who have performed the tests already.

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts
- MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - South America Analysis and Market Forecasts
- MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - US Analysis and Market Forecasts
- MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - Current and Future Players
- MediPoint: Bioabsorbable Stents - EU Analysis and Market Forecasts